Oncogenomics and the development of new cancer therapies

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Nature

• Publication date

  2004-05-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature02627PMID 15164073
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted therapies in the treatment of cancer.

  2005cited by this paper
• Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.

  2004cited by this paper
• Gene Therapy Progress and Prospects: cancer gene therapy using tumour suppressor genes

  2004cited by this paper
• Targeting of Radio-Isotopes for Cancer Therapy

  2004cited by this paper
• The cancer/testis genes: review, standardization, and commentary.

  2004cited by this paper
• Complete sequencing and characterization of 21,243 full-length human cDNAs

  2004cited by this paper
• Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors

  2004cited by this paper
• A real-time PCR assay for DNA-methylation using methylation-specific blockers.

  2004cited by this paper
• Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1

  2004cited by this paper
• NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate.

  2004cited by this paper
• A census of human cancer genes

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation.

  2003cited by this paper
• Receptor tyrosine kinases: the main targets for new anticancer therapy.

  2003cited by this paper
• Phase I study of anticolon cancer humanized antibody A33.

  2003cited by this paper
• Current status of gene therapy for lung cancer and head and neck cancer.

  2003cited by this paper
• Increase of functional diversity by alternative splicing.

  2003cited by this paper
• Sequence-based cancer genomics: progress, lessons and opportunities

  2003cited by this paper
• Identifying tumor origin using a gene expression-based classification map.

  2003cited by this paper
• Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis.

  2003cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.

  2003cited by this paper
• The genetics and genomics of cancer

  2003cited by this paper
• Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.

  2003cited by this paper
• Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins

  2003cited by this paper
• PRAC2: A new gene expressed in human prostate and prostate cancer

  2003cited by this paper
• Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences.

  2003cited by this paper
• Signal transduction--directed cancer treatments.

  2003cited by this paper
• A molecular signature of metastasis in primary solid tumors

  2003cited by this paper
• Technology evaluation: bevacizumab, Genentech/Roche.

  2003cited by this paper
• Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer.

  2003cited by this paper
• A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

  2003cited by this paper
• Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

  2003cited by this paper
• Beyond Herceptin and Gleevec.

  2003cited by this paper
• Phase I studies of ZD1839 in patients with common solid tumors.

  2003cited by this paper
• Targeted therapies for the treatment of cancer.

  2003cited by this paper
• End-sequence profiling: Sequence-based analysis of aberrant genomes

  2003cited by this paper
• Antigen‐specific immunotherapy and cancer vaccines

  2003cited by this paper
• Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing

  2003cited by this paper
• Attrition and Translation

  2003cited by this paper
• The Human Genome Project: Lessons from Large-Scale Biology

  2003cited by this paper
• Cancer vaccines entering Phase III clinical trials

  2003cited by this paper
• Immunochemotherapy: The new standard in aggressive non-Hodgkin's lymphoma in the elderly.

  2003cited by this paper
• High-resolution analysis of genetic events in cancer cells using bacterial artificial chromosome arrays and comparative genome hybridization.

  2003cited by this paper
• Identifying distinct classes of bladder carcinoma using microarrays

  2003cited by this paper
• Natural products as sources of new drugs over the period 1981-2002.

  2003cited by this paper
• The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags

  2003cited by this paper
• Imatinib alone and in combination for chronic myeloid leukemia.

  2003cited by this paper
• New technologies in therapeutic antibody development.

  2003cited by this paper
• Imatinib mesylate in the treatment of chronic myeloid leukaemia

  2003cited by this paper
• Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers

  2003cited by this paper
• The UMD‐p53 database: New mutations and analysis tools

  2003cited by this paper
• 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis.

  2003cited by this paper
• Overview of antibody therapy in B-cell non-Hodgkin's lymphoma.

  2003cited by this paper
• Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.

  2003cited by this paper
• From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes

  2003cited by this paper
• Cancer Specific Viruses and the Development of ONYX-015

  2003cited by this paper
• A new paradigm for drug discovery: integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets.

  2003cited by this paper
• Medicine. The NIH Roadmap.

  2003cited by this paper
• Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies.

  2003cited by this paper
• The NIH Roadmap

  2003cited by this paper
• Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.

  2002cited by this paper
• An international database and integrated analysis tools for the study of cancer gene expression

  2002cited by this paper
• Spectral karyotyping in cancer cytogenetics.

  2002cited by this paper
• Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

  2002cited by this paper
• Identification of cancer/testis genes by database mining and mRNA expression analysis

  2002cited by this paper
• Small molecule inhibitors of the class 1 receptor tyrosine kinase family.

  2002cited by this paper
• The FLEXGene repository: exploiting the fruits of the genome projects by creating a needed resource to face the challenges of the post-genomic era.

  2002cited by this paper
• BAY 43-9006: preclinical data.

  2002cited by this paper
• Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Small molecule inhibitors of the class 1 receptor tyrosine kinase family.

  2002cited by this paper
• STI571 (Gleevec) as a paradigm for cancer therapy.

  2002cited by this paper
• Using the transcriptome to annotate the genome

  2002cited by this paper
• Digital karyotyping

  2002cited by this paper
• Management of malignant gastrointestinal stromal tumours.

  2002cited by this paper
• Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

  2002cited by this paper
• Antibody discovery: phage display.

  2002cited by this paper
• Expression profiling predicts outcome in breast cancer

  2002cited by this paper
• Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Initial sequencing and analysis of the human genome

  2001cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies

  2001cited by this paper
• Cancer/testis (CT) antigens - a new link between gametogenesis and cancer.

  2001cited by this paper
• Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library.

  2001cited by this paper
• Potential clinical application of antioncogene ribozymes for human lung cancer.

  2001cited by this paper
• The sequence of the human genome (abstract only)

  2001cited by this paper
• Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours

  2001cited by this paper
• Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

  2001cited by this paper
• Use of isogenic human cancer cells for high-throughput screening and drug discovery

  2001cited by this paper
• Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.

  2001cited by this paper
• Biodiversity hotspots for conservation priorities

  2000cited by this paper
• Comprehensive genetic analysis of cancer cells

  2000cited by this paper
• Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

  2000cited by this paper
• The Genetic Basis of Human Cancer

  1999cited by this paper
• A public database for gene expression in human cancers.

  1999cited by this paper
• Anti-cancer activity of targeted pro-apoptotic peptides

  1999cited by this paper
• DNA methylation differences associated with tumor tissues identified by genome scanning analysis.

  1998cited by this paper
• The Genetic Basis of Human Cancer

  1997cited by this paper

• Correcting errors in PCR-derived libraries for rare allele detection by reconstructing parental and daughter strand information

  2024cites this paper
• Cancer research and innovation: conceptualising a persistent anomaly

  2023cites this paper
• Recent progress of metal‐based nanomaterials with anti‐tumor biological effects for enhanced cancer therapy

  2023cites this paper
• Novel Pyrido-Thiazolo-Pyrimidinone Hybrids targeting EGFRWT and EGFRT790M: Design, Synthesis, Anticancer Activity and docking simulation

  2023cites this paper
• Bench-to-Bedside: Translational Development Landscape of Biotechnology in Healthcare

  2023cites this paper
• Biomimetic smart nanoplatform for dual imaging-guided synergistic cancer therapy.

  2022cites this paper
• SPERT gene silencing inhibits the growth of human colon cancer xenograft tumor in nude mice via p38MAPK/HSP27 signaling pathway.

  2021cites this paper
• Privacy Concerns regarding Open Medical Data (Preprint)

  2021cites this paper
• Co-expression network analysis identifies key modules and hub genes implicated in esophageal squamous cell cancer progression

  2020cites this paper
• Genomic profiling in gynaecological oncology: the future is now!

  2020cites this paper
• Nanocarriers as Potential Targeted Drug Delivery for Cancer Therapy

  2020cites this paper
• Evolution of cancer genomics and its clinical implications

  2019cites this paper
• Essential role of O-GlcNAcylation in stabilization of oncogenic factors.

  2019cites this paper
• Advances in Proteomics and Bioinformatics

  2018cites this paper
• Computational analysis of next generation sequencing data and its applications in clinical oncology

  2018cites this paper
• [Next generation biobanking: the challenge of data].

  2018cites this paper
• In silico polypharmacology of natural products

  2017cites this paper
• Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis

  2017cites this paper
• Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics.

  2017cites this paper
• Anticancer Drug Combinations, Studies for All Possibilities

  2016cites this paper
• Seq and You Will Find.

  2016cites this paper
• Anticancer Drug Combinations, How Far We can Go Through?

  2016cites this paper
• Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.

  2015cites this paper
• A hyaluronic acid nanogel for photo-chemo theranostics of lung cancer with simultaneous light-responsive controlled release of doxorubicin.

  2015cites this paper
• Cancer Bioinformatics, its Impacts on Cancer Therapy

  2015cites this paper
• Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases

  2015cites this paper
• 6 – Drug combinations

  2015cites this paper
• Individualized cancer chemotherapy via cancer biomarkers or bioinformatics detection

  2015cites this paper
• Anticancer Drug Combinations, A Big Momentum is Needed

  2015cites this paper
• Bioinformatic Analysis for the Validation of Novel Biomarkers for Cancer Diagnosis and Drug Sensitivity

  2015cites this paper
• Cancer Metabolism: Strategic Diversion from Targeting Cancer Drivers to Targeting Cancer Suppliers

  2015cites this paper
• Bioinformatics in Breast Cancer Research

  2015cites this paper
• Anticancer Drug Combinations, Studies from Different Pathways

  2015cites this paper
• Design of Biomedical Robots for the Analysis of Cancer, Neurodegenerative and Rare Diseases

  2015cites this paper
• Personalized Cancer Therapy: A Perspective

  2014cites this paper
• Brenner's Encyclopedia of Genetics 2nd Edition, 7-Volume Set

  2013cites this paper
• Brenner's Encyclopedia of

  2013cites this paper
• Good Intentions, Stubborn Practice: A critical appraisal of a public event on cancer genomics

  2013cites this paper
• Differences in the Binding Affinities of ErbB Family: Heterogeneity in the Prediction of Resistance Mutants

  2013cites this paper
• Incorporating the human gene annotations in different databases significantly improved transcriptomic and genetic analyses.

  2013cites this paper
• The contributors Ontology Outreach Advisory Requirements

  2013cites this paper
• Neoplasia from genetic point of view.

  2013influential citation
• An Empirical Evaluation of Normalization Methods for MicroRNA Arrays in a Liposarcoma Study

  2013cites this paper
• Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.

  2013cites this paper
• Drug Combinations in Cancer Treatments

  2013cites this paper
• Sensitization of prostate cancer cells to cytotoxic drugs induced by the small adenoviral E1A12S protein through multiple cell death/signalling pathways..

  2013cites this paper
• Mass Spectrometry Compatible Enzymatic Assays: Miniaturisation, Automation and Applications

  2013cites this paper
• Linear domain interactome and biological function of anterior gradient 2

  2013cites this paper
• Heat shock protein 90 inhibitors as therapeutic agents.

  2012cites this paper
• Computational framework for systematic and scalable analysis of deep sequencing transcriptomics data

  2012cites this paper
• Microwave Heating of Long-term Formalin-fixed Surgical Pathology Specimens Improves Quality of Extracted DNA

  2012cites this paper
• Human Cancer Classification: A Systems Biology- Based Model Integrating Morphology, Cancer Stem Cells, Proteomics, and Genomics

  2011cites this paper
• Effects of DNA Methyltransferase- and Histone Deacetylase Inhibitors on ALK Positive Anaplastic Large Cell Lymphoma

  2011cites this paper
• Functional proteomics: application of mass spectrometry to the study of enzymology in complex mixtures

  2011cites this paper
• Biobanking: Basic concepts and role in rheumatology

  2011cites this paper
• Molecular targeting of glioblastoma: Drug discovery and therapies.

  2011cites this paper
• A Knowledge Base for Teaching Biology Situated in the Context of Genetic Testing

  2011cites this paper
• Analysis of multi‐arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models

  2010cites this paper
• Decision support based on genomics: Integration of data-and knowledge-driven reasoning

  2010cites this paper
• From Reptilian Phylogenomics to Reptilian Genomes: Analyses of c-Jun and DJ-1 Proto-Oncogenes

  2010cites this paper
• Biospecimen Use in Cancer Research Over Two Decades

  2010cites this paper
• Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms.

  2010cites this paper
• Application of Bioinformatics in Cancer Research

  2010cites this paper
• Cancer driver mutations in protein kinase genes.

  2009cites this paper
• Decitabine and Trichostatin A : a synergistic combination in ALL

  2009cites this paper
• Shock the heat shock network.

  2009cites this paper
• Decitabine and trichostatin A : a synergistic combination in ALL

  2009cites this paper
• Ultrahigh spacing tissue arrays for screening hybridoma by immunohistochemistry.

  2009cites this paper
• Genomics and biology education : complex stuff and curricular overload

  2009cites this paper
• Evolutionary concepts in biobanking - the BC BioLibrary

  2009cites this paper
• Prostate cancer regulatory networks

  2009cites this paper
• CHAPTER 67 – Cancer Genes, Genomes, and the Environment

  2009cites this paper
• Hierarchical Modeling of Activation Mechanisms in the ABL and EGFR Kinase Domains: Thermodynamic and Mechanistic Catalysts of Kinase Activation by Cancer Mutations

  2009cites this paper
• Role of translocated promoter region protein in transcriptional regulation of c jun

  2009cites this paper
• The Emergence of Bioinformatics: Historical Perspective, Quick Overview and Future Trends

  2009cites this paper
• Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90.

  2009cites this paper
• Part One Tumor-associated Antigens ( TAAs ) : Subclasses of TAAs

  2009cites this paper
• Oncogenomics.

  2008cites this paper
• Targeting the Human Cancer Pathway Protein Interaction Network by Structural Genomics*

  2008cites this paper
• An Integrative Analysis of microRNA and mRNA Expression—A Case Study

  2008cites this paper
• Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer

  2007cites this paper
• Viral envelope protein gp64 transgenic mouse facilitates the generation of monoclonal antibodies against exogenous membrane proteins displayed on baculovirus.

  2007cites this paper
• Selective Regression of Cells Expressing Mouse Cytoskeleton-Associated Protein 2 Transcript by Trans-Splicing Ribozyme

  2007cites this paper
• Oncogenic Transcription Factors: Target Genes

  2007cites this paper
• Las Bases Moleculares del Cáncer

  2006cites this paper
• Genoma funcional e análise in silico na caracterização e no isolamento de genes envolvidos em gliomas humanos

  2006cites this paper
• Serial Analysis of Gene Expression

  2006cites this paper
• Suramin as a chemo- and radio-sensitizer: preclinical translational studies

  2006cites this paper
• CHAPTER 8 Gliomas : Quo Vadis

  2006cites this paper
• Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling.

  2006cites this paper
• Gliomas: quo vadis.

  2006cites this paper
• Fates intertwined

  2006cites this paper
• Targeting transcription factors for cancer gene therapy.

  2006cites this paper
• Lineage dependency and lineage-survival oncogenes in human cancer

  2006cites this paper
• Molecular Diagnosis of Chronic Liver Disease and Hepatocellular Carcinoma: The Potential of Gene Expression Profiling

  2006cites this paper
• Prediction of Anticancer Drug Potency from Expression of Genes Involved in Growth Factor Signaling

  2006cites this paper
• Identification of cancer genes by mutational profiling of tumor genomes

  2005cites this paper
• Developing drugs for cognitive impairment in schizophrenia.

  2005cites this paper
• Massive Identification of Cancer-Specific Nucleic Acid Ligands

  2005cites this paper
• Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript.

  2005cites this paper